Miami, FL (May 19, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has signed an exclusive distribution agreement with Apex Services Pakistan to import and distribute Zofin™ to hospitals and clinics in the country. [Read more…]
Organicell Receives Approval In Pakistan For The Use Of Zofin™ For Compassionate Grounds For COVID-19
Clinical Trials To Commence Immediately
Miami, FL (May 11, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced its Zofin™ therapy has been approved by Pakistani regulators to be used for a COVID-19 patient on compassionate grounds. [Read more…]
C-Stem™ outperforms 2D & aggregate cultures in benchmark of cell culture technologies for the mass-production of human induced pluripotent stem cells
TreeFrog Therapeutics presents new data at the 24th Annual Meeting of the American Society for Cell & Gene Therapy.
Bordeaux, France, May 11, 2021 – One month after announcing unprecedented exponential amplification of human pluripotent stem cells (hiPSCs) in a 10L bioreactor French cell therapy company, TreeFrog Therapeutics, released previously unpublished data at the 24th Annual Meeting of the American Society for Cell & Gene Therapy. The findings compare the continuous expansion over 28 days of human induced pluripotent stem cells (hiPSCs) in 2D cell culture, aggregate culture in bioreactor, and bioreactor-based C-StemTM technology. The benchmark demonstrates that C-StemTM outperforms both the 2D and aggregate cell cultures, with a cumulated amplification of over 151 millionfold over 28 days, achieved in only four passages. [Read more…]
Brian C. Handerhan, MBA, Takes on the Newly Created Role of Vice President, Operations for Cell X Technologies, Inc.
CLEVELAND, Ohio – Cell X Technologies’ CEO Peter Johnson MD, today announced an important new hire in Brian C. Handerhan, MBA, who will take on the newly created position of Vice President, Operations. In this role, he will oversee sales, marketing, product development, and product management to drive growth in all cell therapy markets served by Cell X. [Read more…]
Landmark MSC Trial for Parkinson’s Disease Authorized by U.S. FDA
April 28, 2021, SUGAR LAND, Texas — Houston-area non-profit Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a Phase II double-blind placebo controlled clinical trial to assess the efficacy and safety of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells to improve activities of daily living and quality of life in subjects with Parkinson’s Disease.
The trial is the first globally to administer pure adipose-derived mesenchymal stem cells to Parkinson’s patients in such high quantities over repeat treatments. Twenty-four patients will be randomized to receive six intravenous infusions of 200 million stem cells each. [Read more…]
- « Previous Page
- 1
- …
- 70
- 71
- 72
- 73
- 74
- …
- 116
- Next Page »